Advancement highlights Everest’s potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 25, 2022 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical…
- Wednesday, December 6, 2023